PDF herunterladen
CC BY-NC-ND 4.0 · Arch Plast Surg 2022; 49(03): 397-404
DOI: 10.1055/s-0042-1748654
Pediatric/Craniomaxillofacial/Head & Neck
Original Article

Mucormycosis Management in COVID-19 Era: Is Immediate Surgical Debridement and Reconstruction the Answer?

Samarth Gupta
1   Department of Plastic, Reconstructive and Burns Surgery, Sawai Man Singh Hospital, Jaipur, Rajasthan, India
,
Pradeep Goil
1   Department of Plastic, Reconstructive and Burns Surgery, Sawai Man Singh Hospital, Jaipur, Rajasthan, India
,
Arbab Mohammad
3   Aarupadai Veedu Medical College and Hospital, Puducherry, India
,
Joseph M. Escandón
4   Division of Plastic and Reconstructive Surgery, Strong Memorial Hospital, University of Rochester Medical Center, Rochester, New York
› Institutsangaben Funding None.
› Weitere Informationen
   Lizenzen und Reprints

Abstract

Background Excessive use of corticosteroids therapy along with gross immunocompromised conditions in the novel coronavirus disease 2019 (COVID-19) pandemic has raised the risks of contracting opportunistic fungal infections. Here, we describe our experience with the implementation of a surgical protocol to treat and reconstruct rhino-orbital-cerebral mucormycosis.

Methods A retrospective review of our prospectively maintained database was conducted on consecutive patients diagnosed with mucormycosis undergoing immediate reconstruction utilizing our “Mucormycosis Management Protocol.” All patients included in this study underwent reconstruction after recovering from COVID-19. Wide local excision was performed in all cases removing all suspected and edematous tissue. Reconstruction was done primarily after clear margins were achieved on clinical assessment under a cover of injectable liposomal amphotericin B.

Results Fourteen patients were included. The average age was 43.6 years and follow-up was 24.3 days. Thirteen patients had been admitted for inpatient care of COVID-19. Steroid therapy was implemented for 2 weeks in 11 patients and for 3 weeks in 3 patients. Eight patients (57.1%) had a maxillectomy and mucosal lining resection with/without skin excision, and six patients (42.8%) underwent maxillectomy and wide tissue excision (maxillectomy and partial zygomatic resection, orbital exenteration, orbital floor resection, nose debridement, or skull base debridement). Anterolateral thigh (ALT) flaps were used to cover defects in all patients. All flaps survived. No major or minor complications occurred. No recurrence of mucormycosis was noted.

Conclusion The approach presented in this study indicates that immediate reconstruction is safe and reliable in cases when appropriate tissue resection is accomplished. Further studies are required to verify the external validity of these findings.

Keywords

COVID-19 - free tissue flaps - mucormycosis - antifungal agents - reconstructive surgical procedures

Author Contributions

Conceptualization: all authors. Data curation: all authors. Formal analysis: all authors. Funding acquisition: P.G. and S.G. Investigation: all authors. Methodology: all authors. Project administration: all authors. Resources: all authors. Software: all authors. Supervision: P.G. and S.G. Validation: all authors. Visualization: all authors. Writing-original draft: all authors. Writing-review and editing: all authors.


Patient Consent

Informed consent was obtained from all individual participants included in the study.


Supplementary Material



Publikationsverlauf

Artikel online veröffentlicht:
27. Mai 2022

© 2022. The Korean Society of Plastic and Reconstructive Surgeons. This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commercial purposes, or adapted, remixed, transformed or built upon. (https://creativecommons.org/licenses/by-nc-nd/4.0/)

Thieme Medical Publishers, Inc.
333 Seventh Avenue, 18th Floor, New York, NY 10001, USA

 

  • References

  • 1 Song G, Liang G, Liu W. Fungal co-infections associated with global COVID-19 pandemic: a clinical and diagnostic perspective from China. Mycopathologia 2020; 185 (04) 599-606
    CrossrefPubMedGoogle Scholar
  • 2 Cornely OA, Arikan-Akdagli S, Dannaoui E. et al; European Society of Clinical Microbiology and Infectious Diseases Fungal Infection Study Group, European Confederation of Medical Mycology. ESCMID and ECMM joint clinical guidelines for the diagnosis and management of mucormycosis 2013. Clin Microbiol Infect 2014; 20 (Suppl. 03) 5-26
    CrossrefPubMedGoogle Scholar
  • 3 Ibrahim AS, Spellberg B, Walsh TJ, Kontoyiannis DP. Pathogenesis of mucormycosis. Clin Infect Dis 2012; 54 (Suppl. 01) S16-S22
    CrossrefPubMedGoogle Scholar
  • 4 Prabhu RM, Patel R. Mucormycosis and entomophthoramycosis: a review of the clinical manifestations, diagnosis and treatment. Clin Microbiol Infect 2004; 10 (Suppl. 01) 31-47
    CrossrefPubMedGoogle Scholar
  • 5 Tidwell J, Higuera S, Hollier Jr LH. Facial reconstruction after mucormycosis in an immunocompetent host. Am J Otolaryngol 2005; 26 (05) 333-336
    CrossrefPubMedGoogle Scholar
  • 6 Ingram PR, Suthananthan AE, Rajan R. et al. Cutaneous mucormycosis and motor vehicle accidents: findings from an Australian case series. Med Mycol 2014; 52 (08) 819-825
    CrossrefPubMedGoogle Scholar
  • 7 Mignogna MD, Fortuna G, Leuci S. et al. Mucormycosis in immunocompetent patients: a case-series of patients with maxillary sinus involvement and a critical review of the literature. Int J Infect Dis 2011; 15 (08) e533-e540
    CrossrefPubMedGoogle Scholar
  • 8 Petrikkos G, Skiada A, Lortholary O, Roilides E, Walsh TJ, Kontoyiannis DP. Epidemiology and clinical manifestations of mucormycosis. Clin Infect Dis 2012; 54 (Suppl. 01) S23-S34
    CrossrefPubMedGoogle Scholar
  • 9 Kueht M, Villarreal JA, Reece E. et al. Cutaneous mucormycosis in solid organ transplant recipients after Hurricane Harvey: short- and long-term management. Plast Reconstr Surg Glob Open 2019; 7 (01) e2041
    CrossrefPubMedGoogle Scholar
  • 10 Verma DK, Bali RK. COVID-19 and mucormycosis of the craniofacial skeleton: causal, contributory or coincidental?. J Maxillofac Oral Surg 2021; 20 (02) 1-2
    CrossrefPubMedGoogle Scholar
  • 11 Roden MM, Zaoutis TE, Buchanan WL. et al. Epidemiology and outcome of zygomycosis: a review of 929 reported cases. Clin Infect Dis 2005; 41 (05) 634-653
    CrossrefPubMedGoogle Scholar
  • 12 Talmi YP, Goldschmied-Reouven A, Bakon M. et al. Rhino-orbital and rhino-orbito-cerebral mucormycosis. Otolaryngol Head Neck Surg 2002; 127 (01) 22-31
    CrossrefPubMedGoogle Scholar
  • 13 Singh AK, Singh R, Joshi SR, Misra A. Mucormycosis in COVID-19: A systematic review of cases reported worldwide and in India. Diabetes Metab Syndr 2021; 15 (04) 102146
    CrossrefPubMedGoogle Scholar
  • 14 Hosseini SM, Borghei P. Rhinocerebral mucormycosis: pathways of spread. Eur Arch Otorhinolaryngol 2005; 262 (11) 932-938
    CrossrefPubMedGoogle Scholar
  • 15 Claustre J, Larcher R, Jouve T. et al. Mucormycosis in intensive care unit: surgery is a major prognostic factor in patients with hematological malignancy. Ann Intensive Care 2020; 10 (01) 74
    CrossrefPubMedGoogle Scholar
  • 16 Kim JG, Park HJ, Park JH. et al. Importance of immediate surgical intervention and antifungal treatment for rhinocerebral mucormycosis: a case report. J Korean Assoc Oral Maxillofac Surg 2013; 39 (05) 246-250
    CrossrefPubMedGoogle Scholar
  • 17 Srikanth V, Pradeep KN, Anantheswar YN. et al. Cranio-facial mucormycosis—the plastic surgeon's perspective. Eur J Plast Surg 2020; 43: 239-246
    CrossrefGoogle Scholar
  • 18 Spellberg B, Edwards Jr. J, Ibrahim A. Novel perspectives on mucormycosis: pathophysiology, presentation, and management. Clin Microbiol Rev 2005; 18 (03) 556-569
    CrossrefPubMedGoogle Scholar
  • 19 Riley TT, Muzny CA, Swiatlo E, Legendre DP. Breaking the mold: a review of mucormycosis and current pharmacological treatment options. Ann Pharmacother 2016; 50 (09) 747-757
    CrossrefPubMedGoogle Scholar
  • 20 Oswal NP, Gadre PK, Sathe P, Gadre KS. Mucormycosis of mandible with unfavorable outcome. Case Rep Dent 2012; 2012: 257940
    PubMedGoogle Scholar
  • 21 Silberstein E, Krieger Y, Rosenberg N. et al. Facial reconstruction of a mucormycosis survivor by free rectus abdominis muscle flap, tissue expansion, and ocular prosthesis. Ophthal Plast Reconstr Surg 2016; 32 (06) e131-e132
    CrossrefPubMedGoogle Scholar
  • 22 Bhatnagar A, Agarwal A. Naso-orbital fistula and socket reconstruction with radial artery forearm flap following orbital mucormycosis. Natl J Maxillofac Surg 2016; 7 (02) 197-200
    CrossrefPubMedGoogle Scholar
  • 23 Juarez Palacios J, Hanson V, Medina Rendon MA, Lopez-Infante RS. Reconstruction of head and neck mucormycosis: a literature review and own experience in immediate reconstruction. J Reconstr Microsurg Open. 2019; 04: e102-e102
    Artikel in Thieme ConnectGoogle Scholar